A Phase II, Open-Label, Multicenter Study of the GARFT Inhibitor AG2037 [pelitrexol] in Patients With Metastatic Colorectal Cancer Who Failed Treatment With a 5-Fluorouracil/Leucovorin Regimen
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2008
At a glance
- Drugs Pelitrexol (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Dec 2008 Last checked against ClinicalTrials.gov record.
- 22 Jul 2008 New trial record.